OGN Shareholders Sue Over Dividend Deception

Organon promised shareholders dividends were top priority. But after those dividends got slashed to pay down debt, shareholders dumped their Organon stock — and it was the stock price that got slashed next, dropping 27%. Now, enraged investors are fighting back with a class-action lawsuit against the Company.

In late 2024, Organon executives told investors the Company was in great shape. But after acquiring dermatology firm Dermavant, Organon found itself hemorrhaging cash — and fast. While execs publicly insisted the dividend was safe, internally it was another story. Those same executives were preparing to reroute dividend money to pay down the Dermavant debt… they just didn’t let investors in on that news right away.

Then came May 2025, when an earnings report left investors reeling. Organon announced it was slashing dividends and “resetting capital priorities.” Analysts panned the move. Investors raced for the exits, and Organon’s stock nosedived.

Now, more investors are joining the lawsuit.